– Discovery Life Sciences installs the world’s largest commercial fleet of NovaSeq™ X Plus Systems to accelerate genomics research with unprecedented speed and cost-effectiveness
HUNTSVILLE, Ala., March 30, 2023/PRNewswire/ — Discovery Life Sciences™ (Discovery), the Biospecimen and Biomarker Specialists™, has announced that Discovery Genomics is the world’s first commercial services laboratory to receive two of the new NovaSeq™ X Plus sequencing systems from Illumina, Inc. Discovery Genomics will expand its platform to five systems by the end of the year, making it the commercial laboratory with the largest commercial fleet of NovaSeq X Plus in the world.
NovaSeq X Plus is a game changer in genomics, featuring three types of flow cells and generating up to 16 Tb of throughput per run with dual flow cells. Its ultra-high-density flow cells and ultra-high-resolution optics enable up to 26 billion individual readings per flow cell. The system can perform up to four applications per flow cell simultaneously, with built-in secondary analysis capabilities, making it an exceptionally powerful and versatile tool for genomics research.
“We are delighted to be the first commercial services lab in the world to receive two of the new NovaSeq X Plus systems,” said Tom Halsey, MD, Executive Vice President of Discovery Genomics. With the expansion of our fleet to five systems, we are uniquely positioned to provide the greatest capacity to generate genomic data more cost-effectively, furthering our mission to enable our clients’ success by delivering world-class genomic services with speed. , scale and quality”.
Discovery Genomics scientists are immediately beginning the necessary bridge studies to validate workflows from existing sequencers to NovaSeq X Plus, which will expedite the transfer of customer projects to the most efficient and cost-effective platform. The X Plus, combined with individually addressable flow cell lanes, flexible run options, and simplicity of operation, will enable Discovery Genomics to offer market-leading speed and scale to deliver the highest quality results at substantially reduced costs and timelines.
“Cross-validation of our existing WGS, WES, and RNA-Seq libraries for standard and low-input workflows on the newly installed Illumina NovaSeq X Plus instruments has already begun,” said Dr. Nripesh Prasad, vice president of scientific and technical development. from Discovery Genomics. This cross-validation data will help us quickly bring NovaSeq 6000 and X-Plus chemistries together so customers can confidently use the new technology for their high-throughput projects at unprecedented speed and scale, while lowering total costs. of the project”.
Discovery’s CLIA-certified, CAP-accredited, and GCLP-compliant genomics laboratory offers a broad range of scalable next-generation sequencing (NGS) services, including RNA, whole exome, whole genome, targeted, single-cell, and epigenetic sequencing . Its patented workflow for complete genomic profiling enables interrogation of the most difficult sample types, such as formalin-fixed paraffin-embedded (FFPE) and core needle biopsies (CNB).
Discovery Life Sciences will relocate this summer to a new 100,000-square-foot global headquarters, offering one of the largest facilities for cutting-edge multi-omics biomarker technologies, including Illumina NovaSeq X Plus systems, under one roof. The facilities will house laboratories for genomics, proteomics, molecular pathology, and flow cytometry. A fully integrated LIMS system will track the chain of custody of a research sample or clinical trial from receipt through multiple technologies, producing complete and actionable data in the shortest possible time.
About Discovery Life Sciences
Discovery Life Sciences is the specialist biospecimen, biomarker and proteogenomics company, combining the world’s largest commercial biospecimen inventory and acquisition network with preeminent laboratories for multiomics biomarker services, including genomics, tissue biomarker, proteomics and cellular services for accelerate new therapies supported by biomarker programs and companion diagnostics for cancer, infectious diseases, and other rare and complex conditions.
Through AllCells®, our cell and gene therapy division, we maintain the largest pool of recoverable donors to supply clinical-grade, research-only (RUO) fresh and cryopreserved human cell materials to support cell and gene therapy programs in any stage of development and at any scale.
Driven by leading scientific expertise and innovative use of today’s technologies, the Discovery team is committed to helping clients quickly overcome obstacles and deliver results to make critical research and development decisions at market-leading speed. We are science at your service™! For more information, visit dls.com.
Logo – https://mma.prnewswire.com/media/1022478/Discovery_LS_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/discovery-life-sciences-instala-la-mayor-flota-comercial-del-mundo-de-sistemas-novaseq-x-plus-301786169.html
